Alexandra L. Quittner reports research funding from the FDA (Food and Drug Administration), CF Foundation; consulting and speaker’s fees from Vertex Pharmaceuticals; licensing fees through IQVIA.
REFERENCES :
  1. Quittner, A. L., Alpern, A. N., Wolin, D., McLeod, L., Downey, C., Nelson, L., & Khandelwal, N. Psychometric analyses of a new gi symptom tracker for cystic fibrosis. Ped Pulmonol abstract published 2017, 52 , S453.
  2. Smith S, Rowbotham N, Davies G, Gathercole K, Collins SJ, Elliott Z, Herbert S, Allen L, Ng C, Smyth A. How can we relieve gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey. BMJ Open Respir Res. 2020 Sep;7(1):e000614. doi: 10.1136/bmjresp-2020-000614. PMID: 32900780; PMCID: PMC7478045.
  3. Raun AMT, Brekke G, Mølgaard C, Jaudszus A, Mainz JG, Pressler T, Skov M. Impact of timing of PERT on gastrointestinal symptoms in Danish children and adolescents with CF. Acta Paediatr. 2022 Feb;111(2):432-439. doi: 10.1111/apa.16143. Epub 2021 Oct 28. PMID: 34626004.
  4. Gabel ME, Galante GJ, Freedman SD. Gastrointestinal and Hepatobiliary Disease in Cystic Fibrosis. Semin Respir Crit Care Med. 2019 Dec;40(6):825-841. doi: 10.1055/s-0039-1697591. Epub 2019 Oct 28. PMID: 31659728.
  5. Boon M, Claes I, Havermans T, Fornés-Ferrer V, Calvo-Lerma J, Asseiceira I, Bulfamante A, Garriga M, Masip E, Woodcock S, Walet S, Barreto C, Colombo C, Crespo P, Van der Wiel E, Hulst J, Martinez-Barona S, Nobili R, Pereira L, Ruperto M, Vicente S, De Boeck K, Ribes-Koninckx C; MyCyFAPP consortium. Assessing gastro-intestinal related quality of life in cystic fibrosis: Validation of PedsQL GI in children and their parents. PLoS One. 2019 Dec 20;14(12):e0225004. doi: 10.1371/journal.pone.0225004. PMID: 31860639; PMCID: PMC6924691.
  6. Mainz JG, Zagoya C, Polte L, Naehrlich L, Sasse L, Eickmeier O, Smaczny C, Barucha A, Bechinger L, Duckstein F, Kurzidim L, Eschenhagen P, Caley L, Peckham D, Schwarz C. Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score. Front Pharmacol. 2022 Jun 3;13:877118. doi: 10.3389/fphar.2022.877118. PMID: 35721187; PMCID: PMC9203829.
  7. Southern KW, Castellani C, Lammertyn E, Smyth A, VanDevanter D, van Koningsbruggen-Rietschel S, Barben J, Bevan A, Brokaar E, Collins S, Connett GJ, Daniels TWV, Davies J, Declercq D, Gartner S, Gramegna A, Hamilton N, Hauser J, Kashirskaya N, Kessler L, Lowdon J, Makukh H, Martin C, Morrison L, Nazareth D, Noordhoek J, O’Neill C, Owen E, Oxley H, Raraigh KS, Raynal C, Robinson K, Roehmel J, Schwarz C, Sermet I, Shteinberg M, Sinha I, Takawira C, van Mourik P, Verkleij M, Waller MD, Duff A. Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis. J Cyst Fibros. 2023 Jan;22(1):17-30. doi: 10.1016/j.jcf.2022.10.002.
  8. Schwarzenberg SJ, Vu PT, Skalland M, Hoffman LR, Pope C, Gelfond D, Narkewicz MR, Nichols DP, Heltshe SL, Donaldson SH, Frederick CA, Kelly A, Pittman JE, Ratjen F, Rosenfeld M, Sagel SD, Solomon GM, Stalvey MS, Clancy JP, Rowe SM, Freedman SD; Promise Study Group. Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI. J Cyst Fibros. 2023 Mar;22(2):282-289. doi: 10.1016/j.jcf.2022.10.003. Epub 2022 Oct 21. PMID: 36280527; PMCID: PMC10144072.
  9. Henen S, Denton C, Teckman J, Borowitz D, Patel D. Review of Gastrointestinal Motility in Cystic Fibrosis. J Cyst Fibros. 2021 Jul;20(4):578-585. doi: 10.1016/j.jcf.2021.05.016. Epub 2021 Jun 17. PMID: 34147362.
  10. Brownell JN, Bashaw H, Stallings VA. Growth and Nutrition in Cystic Fibrosis. Semin Respir Crit Care Med. 2019 Dec;40(6):775-791. doi: 10.1055/s-0039-1696726. Epub.
  11. Fung TC. The microbiota-immune axis as a central mediator of gut-brain communication. Neurobiol Dis. 2020 Mar;136:104714. doi: 10.1016/j.nbd.2019.104714. Epub 2019 Dec 14. PMID: 31846737.
  12. Waclawiková B, El Aidy S. Role of Microbiota and Tryptophan Metabolites in the Remote Effect of Intestinal Inflammation on Brain and Depression. Pharmaceuticals (Basel). 2018 Jun 25;11(3):63. doi: 10.3390/ph11030063. PMID: 29941795; PMCID: PMC6160932.
  13. Quittner AL, Goldbeck L, Abbott J, Duff A, Lambrecht P, Solé A et al. Prevalence of depression and anxiety in patients with cystic fibrosis and parent caregivers: results of The International Depression Epidemiological Study across nine countries. Thorax 2014;69: 1090–7. doi.org/10.1136/thoraxjnl-2014-205983.
  14. Tomaszek L, Dębska G, Cepuch G, Kulpa M, Pawlik L, Broniatowska E. Evaluation of quality of life predictors in adolescents and young adults with cystic fibrosis. Heart Lung. 2019 Mar-Apr;48(2):159-165. doi: 10.1016/j.hrtlng.2018.08.003. Epub 2018 Oct 10. PMID: 30316456.
  15. Verkleij M, de Winter D, Hurley MA, Abbott J. Implementing the International Committee on Mental Health in Cystic Fibrosis (ICMH) guidelines: Screening accuracy and referral-treatment pathways. J Cyst Fibros. 2018 Nov;17(6):821-827. doi: 10.1016/j.jcf.2018.02.005. Epub 2018 Mar 2. PMID: 29503039.
  16. Verkleij M, Georgiopoulos AM, Barendrecht H, Friedman D. Pilot of a therapist-guided digital mental health intervention (eHealth CF-CBT) for adults with cystic fibrosis. Pediatr Pulmonol. 2023 Jul;58(7):2094-2103. doi: 10.1002/ppul.26438. Epub 2023 May 5. PMID: 37144856.
  17. Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015 Apr-Jun;28(2):203-209. PMID: 25830558; PMCID: PMC4367209.
  18. Hayee B, Watson KL, Campbell S, Simpson A, Farrell E, Hutchings P, Macedo P, Perrin F, Whelan K, Elston C. A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders. United European Gastroenterol J. 2019 Aug;7(7):881-888. doi: 10.1177/2050640619841545. PMID: 31428412; PMCID: PMC6683632.
  19. Shoff SM, Tluczek A, Laxova A, Farrell PM, Lai HJ. Nutritional status is associated with health-related quality of life in children with cystic fibrosis aged 9-19 years. J Cyst Fibros. 2013 Dec;12(6):746-53. doi: 10.1016/j.jcf.2013.01.006. Epub 2013 Feb 12. PMID: 23410621; PMCID: PMC3683079.
  20. Stephenson AL, Mannik LA, Walsh S, Brotherwood M, Robert R, Darling PB, Nisenbaum R, Moerman J, Stanojevic S. Longitudinal trends in nutritional status and the relation between lung function and BMI in cystic fibrosis: a population-based cohort study. Am J Clin Nutr. 2013 Apr;97(4):872-7. doi: 10.3945/ajcn.112.051409. Epub 2013 Feb 6. PMID: 23388659.
  21. Verkleij M, Hofsteenge H, Quittner A. P247 Dutch translation of the gastrointestinal (GI) symptom tracker for people with cystic fibrosis. J Cyst Fibros., abstract published on 01 June 2022. DOI: 10.1016/S1569-1993(22)00576-8.
  22. Boon M, Claes I, Havermans T, Fornés-Ferrer V, Calvo-Lerma J, Asseiceira I, Bulfamante A, Garriga M, Masip E, Woodcock S, Walet S, Barreto C, Colombo C, Crespo P, Van der Wiel E, Hulst J, Martinez-Barona S, Nobili R, Pereira L, Ruperto M, Vicente S, De Boeck K, Ribes-Koninckx C; MyCyFAPP consortium. Assessing gastro-intestinal related quality of life in cystic fibrosis: Validation of PedsQL GI in children and their parents. PLoS One. 2019 Dec 20;14(12):e0225004. doi: 10.1371/journal.pone.0225004. PMID: 31860639; PMCID: PMC6924691.
  23. Tabori H, Arnold C, Jaudszus A, Mentzel HJ, Renz DM, Reinsch S, Lorenz M, Michl R, Gerber A, Lehmann T, Mainz JG. Abdominal symptoms in cystic fibrosis and their relation to genotype, history, clinical and laboratory findings. PLoS One. 2017 May 4;12(5):e0174463. doi: 10.1371/journal.pone.0174463. PMID: 28472055; PMCID: PMC5417419.
  24. Boon M, Calvo-Lerma J, Claes I, Havermans T, Asseiceira I, Bulfamante A, Garriga M, Masip E, van Schijndel BAM, Fornes V, Barreto C, Colombo C, Crespo P, Vicente S, Janssens H, Hulst J, Witters P, Nobili R, Pereira L, Ruperto M, Van der Wiel E, Mainz JG, De Boeck K, Ribes-Koninckx C. Use of a mobile application for self-management of pancreatic enzyme replacement therapy is associated with improved gastro-intestinal related quality of life in children with Cystic Fibrosis. J Cyst Fibros. 2020 Jul;19(4):562-568. doi: 10.1016/j.jcf.2020.04.001. Epub 2020 Apr 22. PMID: 32335023.
  25. Castor EDC. https://www.castoredc.com/
  26. Spitzer, R. L., Kroenke, K., Williams, J. B., & Löwe, B. (2006). A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 166:1092-7. doi: 10.1001/archinte.166.10.1092.
  27. Hinz, A., Klein, A. M., Brähler, E., Glaesmer, H., Luck, T., Riedel-Heller, S. G., … & Hilbert, A. (2017). Psychometric evaluation of the Generalized Anxiety Disorder Screener GAD-7, based on a large German general population sample. J Affect Disord. 210:338-44. doi: 10.1016/j.jad.2016.12.012.
  28. Kroenke, K., Spitzer, R. L., & Williams, J. B. (2001). The PHQ‐9: validity of a brief depression severity measure. J Gen Intern Med. 1:606-13. doi: 10.1046/j.1525-1497.2001.016009606.x.
  29. Manea, L., Gilbody, S., & McMillan, D. (2012). Optimal cut-off score for diagnosing
depression with the Patient Health Questionnaire (PHQ-9): a meta-analysis. CMAJ. 184:E191-6. doi: 10.1503/cmaj.110829.
  1. Klijn, P. H., van Stel, H. F., Quittner, A. L., van der Net, J., Doeleman, W., van der Schans, C. P., & van der Ent, C. K. (2004). Validation of the Dutch cystic fibrosis questionnaire (CFQ) in adolescents and adults. Journal of Cystic Fibrosis, 3(1), 29-36.
  2. Quittner AL, Sawicki GS, McMullen A, Rasouiliyan L, Pasta DJ, Yegin A, et al. Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample. Quality of Life Research 2012;21(7):1279-90.
  3. Retsch-Bogart, GZ, Quittner AL, Gibson, RL, Oermann CM, McCoy, KS, Montgomery, AB, et al. Efficacy and Safety of Inhaled Aztreonam Lysine for Airway Pseudomonas in Cystic Fibrosis. Chest 2009;135(5):1223-32.
  4. Ramsey BW, Davies J, McElvaney GN, Tullis E, Bell SC, Dřevínek P et al. for the VX08-770-102 Study Group. New Engl J Med 2011;365(18):1663-72.
  5. Guo J, Garratt A, Hill A. Worldwide rates of diagnosis and effective treatment for cystic fibrosis. J Cystic Fibrosis. 2022;21(3):456‐462.
  6. Mall MA, Brugha R, Gartner S, et al. Efficacy and safety of elexacaftor/tezacaftor/ivacaftor in children 6 through 11 years of age with cystic fibrosis heterozygous for F508del and a minimal function mutation: a phase 3B, randomized, placebo‐controlled study. Am J Respir Crit Care Med. 2022.
  7. Graziano S, Boldrini F, Pellicano GR, Milo F, Majo F, Cristiani L, Montemitro E, Alghisi F, Bella S, Cutrera R, Fiocchi AG, Quittner A, Tabarini P. Longitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor: Multidimensional Assessment of Neuropsychological Side Effects and Physical and Mental Health Outcomes in Adolescents and Adults. Chest. 2023 Nov 3:S0012-3692(23)05689-1. doi: 10.1016/j.chest.2023.10.043. Epub ahead of print. PMID: 37925143.
  8. Ooi, C.Y., Syed, S.A., Rossi, L. et al. Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation. Sci Rep 8, 17834 (2018). https://doi.org/10.1038/s41598-018-36364-6.
  9. Karb DB, Cummings LC. The Intestinal Microbiome and Cystic Fibrosis Transmembrane Conductance Regulator Modulators: Emerging Themes in the Management of Gastrointestinal Manifestations of Cystic Fibrosis. Curr Gastroenterol Rep. 2021 Aug 27;23(10):17. doi: 10.1007/s11894-021-00817-2. PMID: 34448955.
  10. Fajac I, Daines C, Durieu I, Goralski JL, Heijerman H, Knoop C, Majoor C, Bruinsma BG, Moskowitz S, Prieto-    Centurion V, Van Brunt K, Zhang Y, Quittner A. Non-respiratory health-related quality of life in people with cystic fibrosis  receiving elexacaftor/tezacaftor/ivacaftor. J Cyst Fibros. 2022 Sep 13:S1569-1993(22)00655-5. doi: 10.1016/j.jcf.2022.08.018. Epub ahead of print. PMID: 36114142.
  11. Bathgate CJ, Muther E, Georgiopoulos AM, Smith B, Tillman L, Graziano S, Verkleij M, Lomas P, Quittner A. Positive and negative impacts of elexacaftor/tezacaftor/ivacaftor: Healthcare providers’ observations across US centers. Pediatr Pulmonol. 2023 Sep;58(9):2469-2477. doi: 10.1002/ppul.26527. Epub 2023 Jun 2. PMID: 37265418.
  12. Seaton N, Hudson J, Harding S, Norton S, Mondelli V, Jones ASK, Moss-Morris R. Do interventions for mood improve inflammatory biomarkers in inflammatory bowel disease?: a systematic review and meta-analysis. EBioMedicine. 2024 Feb;100:104910. doi: 10.1016/j.ebiom.2023.104910. Epub 2024 Jan 24. PMID: 38272759; PMCID: PMC10878994.
  13. Mukhtar K, Nawaz H, Abid S. Functional gastrointestinal disorders and gut-brain axis: What does the future hold? World J Gastroenterol. 2019 Feb 7;25(5):552-566. doi: 10.3748/wjg.v25.i5.552. PMID: 30774271; PMCID: PMC6371005.
  14. Quittner AL, Abbott J, Hussain S, et al. Integration of mental health screening and treatment into cystic fibrosis clinics: evaluation of initial implementation in 84 programs across the United States. Pediatr Pulmonol 2020; 5: 2995–3004.